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Late-onset cytomegalovirus (CMV) disease is a signif-
icant problem with a standard 3-month prophylaxis
regimen. This multicentre, double-blind, randomized
controlled trial compared the efficacy and safety of 200
days’ versus 100 days’ valganciclovir prophylaxis (900
mg once daily) in 326 high-risk (D+/R–) kidney allograft
recipients. Significantly fewer patients in the 200-day
group versus the 100-day group developed confirmed
CMV disease up to month 12 posttransplant (16.1%
vs. 36.8%; p < 0.0001). Confirmed CMV viremia was
also significantly lower in the 200-day group (37.4%
vs. 50.9%; p = 0.015 at month 12). There was no sig-
nificant difference in the rate of biopsy-proven acute
rejection between the groups (11% vs. 17%, respec-
tively, p = 0.114). Adverse events occurred at simi-
lar rates between the groups and the majority were
rated mild-to-moderate in intensity and not related to
study medication. In conclusion, this study demon-
strates that extending valganciclovir prophylaxis (900
mg once daily) to 200 days significantly reduces the
incidence of CMV disease and viremia through to
12 months compared with 100 days’ prophylaxis, with-
out significant additional safety concerns associated
with longer treatment. The number needed to treat to
avoid one additional patient with CMV disease up to
12 months posttransplant is approximately 5.
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Introduction
Cytomegalovirus (CMV) remains one of the most impor-
tant infections in solid organ transplant (SOT) recipients
and is associated with significant morbidity and occasional
mortality (1–3). Direct effects attributed to CMV infection
include viral syndrome or tissue invasive disease (4). Indi-
rect effects may include an increased risk of allograft re-
jection (5), opportunistic infections and posttransplantation
diabetes mellitus (6). The risk of CMV disease is highest in
seronegative recipients (R−) of seropositive donors (D+),
and in patients who are heavily immunosuppressed such
as those receiving antilymphocyte antibody therapy as in-
duction or for treatment of rejection (1,7).
CMV prophylaxis is now widely used in the transplantation
setting and has been associated with reductions in CMV
disease, mortality and graft rejection in high-risk patients
(8–10). Until recently, the emphasis on prophylaxis with
these agents has focused on early disease occurring <3
months after transplantation, with the duration of prophy-
laxis typically no longer than 3 months (7). However, it is
well recognized now that standard courses of antiviral pro-
phylaxis are associated with a significant incidence of late-
onset CMV disease. This is generally defined as CMV dis-
ease occurring after 3 months posttransplant. Late-onset
CMV disease has the potential to cause significant mor-
bidity and has been associated with increased mortality
(11). In addition, these patients may present with nonspe-
cific or atypical symptoms, resulting in delays in diagnosis
(12–14).
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Valganciclovir CMV Prophylaxis: 100 Versus 200 Days
With a standard 3-month course of prophylaxis, late-onset
disease generally occurs between months 3 and 6. There-
fore, prolongation of prophylaxis to 6 months or longer
has been proposed as a potential strategy to decrease the
incidence of CMV disease (12,15,16). This study was un-
dertaken in order to compare the efficacy and safety of 200
days of valganciclovir prophylaxis with 100 days of prophy-
laxis for prevention of CMV disease in high-risk (D+/R–)
kidney allograft recipients.
Methods
Study design and patient population
This was a multicentre, double-blind, randomized placebo-controlled study
comparing the efficacy and safety of 200 days’ valganciclovir prophylaxis
with 100 days’ valganciclovir prophylaxis (900 mg once daily adjusted for
renal function in both cases) for the prevention of CMV disease in high-risk
(D+/R−) kidney allograft recipients. All patients provided signed informed
consent. The study was conducted in full accordance with the principles
of the Declaration of Helsinki and Good Clinical Practice guidelines and
adhered with local and national regulatory requirements and laws. The trial
was registered at clinicaltrials.gov (NCT00294515).
Eligible patients were kidney allograft recipients aged ≥16 years who were
seronegative for CMV prior to transplant and who received an organ from
a CMV seropositive donor (D+/R−). All patients were required to have
adequate hematological assessments and renal function (defined as a crea-
tinine clearance >10 mL/min by day 10 posttransplant), and be able to toler-
ate and commence oral study medication within 10 days of their transplant.
Reasons for exclusion from the study included: suspected CMV disease at
enrolment, HIV, hepatitis B or hepatitis C; use of anti-CMV therapy within
30 days prior to study; multiple organ transplantation; allergies or previous
adverse reactions to acyclovir, valacyclovir, ganciclovir or valganciclovir; se-
vere uncontrolled diarrhea or evidence of malabsorption; liver function tests
>3 times the upper level of normal (ULN); serious psychiatric or medical
disorder; male with a pregnant partner; or lactation. Women of childbearing
potential were required to have a negative pregnancy test at screening and
to use effective birth control throughout the study. Male patients were ad-
vised to use a barrier method of contraception during the study and for at
least 90 days following cessation of study medication.
Patients were randomized sequentially in 1:1 ratio at each study centre in
the order in which they were enrolled to receive valganciclovir 900 mg daily
for 200 days, or for 100 days followed by 100 days of placebo. Treatment
with the study drug was initiated as soon as the patient was able to toler-
ate oral medication following surgery, but no later than 10 days posttrans-
plant, and was continued to Day 200 posttransplant. Intravenous ganciclovir
(5 mg/kg/day) was permitted for patients initially unable to tolerate oral med-
ication and could be administered until Day 10 posttransplant or until the
patient could tolerate oral medication, whichever was sooner.
Study treatment was initiated at the recommended dosage of two 450
mg tablets once a day with doses to be taken within 30 min of break-
fast. Patients with reduced renal function based upon calculated creatinine
clearance (CrCl; calculated from serum creatinine using the Cockcroft–Gault
formula) had dosages adjusted in accordance with standard recommenda-
tions. Patients with CrCl <10 mL/min or who required dialysis had their
study medication interrupted, but could resume medication once CrCl in-
creased to ≥10 mL/min provided they had not missed >14 consecutive
days of study medication, or more than 21 days in any given 28-day period.
In this study, patients with either CMV viral syndrome or tissue invasive
CMV were considered to have CMV disease. Patients with suspected CMV
disease had a blood sample taken, which was divided and analyzed lo-
cally and at a central laboratory. Patients found to have CMV disease, were
treated in accordance with local practice. CMV syndrome was defined as
CMV viremia identified by quantitative PCR (or pp65 antigenemia and other
sponsor-approved CMV assays) and at least one of the following: a fever
≥38◦C; new onset severe malaise; leukopenia on two successive measure-
ments separated by at least 24 hours (defined as a white blood cell [WBC]
count of <3500 cells/lL if presymptomatic count was ≥4000 cells/lL or
a decrease in WBC of >20% if the presymptomatic count was <4000
cells/lL); atypical lymphocytosis of ≥5%; thrombocytopenia (defined as
a platelet count of <100,000 cells/lL if the prior count was ≥115,000
cells/lL or a decrease of >20% if the prior count was <115,000 cells/lL);
or elevation of hepatic transaminases to ≥2 × ULN. Tissue invasive CMV
was defined as evidence of localized CMV infection (CMV inclusion cells,
in situ detection of CMV antigen, cell culture or DNA by immunostain or
hybridization, respectively) in a biopsy or other appropriate specimen (e.g.
bronchoalveolar lavage, cerebral spinal fluid) and symptoms of organ dys-
function. Definitions of CMV disease were consistent with current AST
guidelines for use in clinical trials (17). No routine monitoring for CMV
viremia was allowed during the study, unless as part of the management
of an established CMV infection. However, plasma samples were collected
at monthly intervals for the first 12 months posttransplant and for cause
viral load assessment in case of suspect CMV disease; these were sent to
a central laboratory for viral load testing (Roche Cobas Amplicor). The data
were used for retrospective analysis, but not revealed to the investigators.
Efficacy
The primary efficacy parameter was the proportion of D+/R− patients who
developed CMV disease (CMV syndrome or tissue invasive CMV) within the
first 52 weeks. Secondary efficacy parameters included the proportion of
patients with CMV disease at 6 and 9 month posttransplant, the proportion
of patients with CMV viremia, the proportion of patients who experienced
biopsy-proven acute rejection (BPAR), the proportions of patients with graft
loss, the proportion of patients surviving, the proportion of patients with
opportunistic infections and the proportion of patients experiencing post-
transplantation diabetes mellitus.
Safety
Safety was evaluated by clinical assessment including vital signs, laboratory
analyses, adverse events and opportunistic infections.
Statistical methods
Sample size was calculated as follows. A two-group continuity-corrected
chi-square test with a 0.05 two-sided significance level has 80% power to
detect a difference between the two groups if the CMV disease rate in the
200-day valganciclovir prophylaxis group was 15% and that in the 100-day
valganciclovir prophylaxis group was 30% (odds ratio 0.412) when the
sample size in each group is 134 patients. Assuming a premature termina-
tion rate of approximately 15%, 158 patients per arm (316 patients in total)
would be required in the study to ensure 134 patients per arm complete the
full course of treatment with 52 weeks follow-up or reach primary endpoint.
The patient populations analyzed included the intent-to-treat (ITT) population
(all patients who were randomized, who were D+/R− and who received at
least one dose of study drug) and the safety population (all patients who
were randomized, who received at least one dose of study medication and
who had at least one postrandomization safety assessment).
The null hypothesis of no difference in the proportion of patients
responding in each treatment group was tested using the stratified
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Cochran–Mantel–Haenszel analysis for the primary endpoint. No adjust-
ments were made for multiple statistical testing. Secondary endpoints
measured as time to event were summarized using life table methods




Figure 1 outlines the trial flow for all randomized patients;
326 patients were randomized from 65 centers in 13 coun-
tries. The groups were well balanced with respect to pa-
tient baseline demographics (Table 1). All patients were
between the ages of 17 and 77 years, with more men
than women randomized in both treatment groups. A to-
tal of 123/160 (76.9%) patients in the 200-day group and
94/166 (56.6%) patients in the 100-day group completed
the entire course (approximately 200 days) of prophylaxis
with study medication (100 days of valganciclovir followed
by 100 days of either valganciclovir or placebo): 33 (21.1%)
and 70 (42.7%) patients withdrew from treatment, respec-
tively, with the difference between groups mainly due to
a high rate of insufficient treatment response in the 100-
day group (i.e. development of CMV disease) (4 vs. 47
patients). Overall, 25 and 26 patients, respectively, prema-
turely withdrew from the study by week 52.
Although the two groups were well balanced with respect
to use of intravenous ganciclovir during the period up to 10
days posttransplant, the majority of the safety population
did not receive intravenous ganciclovir (120 [77%] vs. 130
[79%]). Of those that did receive intravenous ganciclovir
(36 [23%] and 34 [21%]), 13 patients in the 200-day group
had 5 or more days of intravenous ganciclovir treatment
compared with 17 patients in the 100-day group.
Efficacy
CMV disease: The Kaplan–Meier curve showing the time
to development of CMV disease is shown in Figure 2. The
incidence of CMV disease by 12 months posttransplant
was 25/155 (16.1%) in the 200-day compared to 60/163
(36.8%) in the 100-day group; p < 0.0001. The lower in-
cidence of CMV disease in the 200-day group was ev-
ident at 6 and 9 months posttransplant (p < 0.0001 at
both time points) (see Table 2). The vast majority of CMV
disease was classified as CMV syndrome (83/85 [97.6%]
total disease cases). CMV syndrome was rated by the in-
vestigator as mild-to-moderate in severity in most cases
(20/24 [83.3%] in the 200-day group and 45/59 [76.3%]
in 100-day group). The most common presenting symp-
toms were fever, malaise and leukopenia in both groups.
All 24 patients with CMV syndrome in the 200-day group
and 96.6% (57/59) of those with CMV syndrome in the
Randomization (n=326)
Allocated 200 day valganciclovir 
prophylaxis (n=160)
Received treatment and had post-
randomization safety assessment  
(safety population; n= 156)
Received treatment and D+/R-
(ITT population; n= 155)
Allocated 100 day valganciclovir 
prophylaxis (n=166) 
Received treatment and had post-
randomization safety assessment  
(safety population; n= 164)
Received treatment and D+/R-
(ITT population; n= 163)
Withdrew from treatment (n=33)
• Adverse events (n=17)
• Insufficient treatment response (n=4)
• Refused treatment (n=7)
• Other (n=5)
Withdrew from study (n=25)
Withdrew from treatment (n=70)
• Adverse events (n=10)
• Insufficient treatment response (n=47)
• Refused treatment (n=4)
• Other (n=9)
Withdrew from study (n=26) Figure 1: Patient flow through
the study.
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Table 1: Patient characteristics at baseline (safety population)
Valganciclovir Valganciclovir
200 day 100 day
(n = 156) (n = 164)
Male, n (%) 116 (74%) 119 (73%)
Ethnicity, n (%)
White 138 (89%) 141 (87%)
Mean age, years (SD) 47.0 (13.5) 48.5 (13.8)
Primary reason for transplant, n (%)
Glomerulonephritis 22 (14%) 32 (20%)
Cystic/polycystic
kidney disease
20 (13%) 24 (15%)
Diabetes mellitus 24 (15%) 23 (14%)
Hypertension 19 (12%) 21 (13%)
Pyelo/interstitial
nephritis
7 (4%) 9 (5%)
Other 64 (41%) 55 (34%)
Primary transplant 145 (93%) 149 (91%)
Induction therapy at
transplant1




79 (51%) 72 (44%)
Antilymphocyte
antibodies
52 (33%) 52 (32%)
Delay to start of study medication
No delay 103 (66%) 119 (73%)
Delayed graft
function
30 (19%) 25 (15%)
Unable to tolerate
study medication
6 (4%) 6 (4%)
Other 17 (11%) 14 (9%)
SD = standard deviation.
1Some patients may have received both.
100-day group received treatment for their symptoms. Tis-
sue invasive disease was uncommon. Only one patient in
the 200-day group and two patients in the 100-day group
had biopsy-confirmed tissue invasive CMV disease (on day
215 and days 119 and 132, respectively). All three cases of
tissue invasive disease were gastrointestinal (one case of
gastroenteritis in each group, and colitis and duodenitis).
All cases of tissue invasive CMV disease resolved with
treatment with intravenous ganciclovir or valganciclovir.
CMV viremia: CMV viremia analysis was performed
using all central laboratory viral load data including for-
cause viral loads and regular (i.e. blinded) interval viral
load testing. The time to onset of viremia (viral load >600
copies/mL) was longer in the 200-day group than in the
100-day group (p < 0.001; Figure 3). The incidence of
CMV viremia by 12 months posttransplant was signifi-
cantly lower in the 200-day group (p = 0.015) compared
to the 100-day group (Table 2). Viremia was also signifi-
cantly lower in patients in the 200-day group as early as
6 months (p < 0.0001) posttransplant and at 9 months
(p = 0.013). In general, the peak CMV viral load was lower
in the 200-day group compared with the 100-day group
(Figure 4); the proportion of patients with the highest peak
in viral load (>100 000 copies/mL) was 2.6% and 11.0%
in the two groups, respectively. The incidence of asymp-
tomatic viremia (i.e. patients who had viral load >600
copies/mL, but were not reported by the investigator as
having CMV disease because they had no symptoms) was
similar in both groups: 34 patients (21.9%) versus 30 pa-
tients (18.4%) in the 200-day versus the 100-day groups,
respectively.
Acute rejection and graft function: There was a trend
toward less BPAR in the 200-day group versus the 100-day
group (11% vs. 17%, respectively, p = 0.114) (Table 2).
Most patients experienced BPAR before 100 days in both
treatment groups: 10 out of 17 versus 15 out of 28 in the
200-day versus the 100-day group, respectively, and the
rest of the cases were spread throughout the remaining
time to 12 months. Very few patients experienced graft
loss during the study and the rate was similar for both
treatment arms (p = 0.934). The two treatment groups
were broadly similar with respect to renal function.
Serum creatinine levels declined for both treatment groups
over the first 4 weeks posttransplant and then remained
stable thereafter (Figure 5). Significantly impaired renal
function, defined as serum creatinine level of >2.5 mg/dL
(221 lmol/L), was observed in 14% and 17% of patients,
respectively, up to 28 days after completion of study
medication.
Safety
The majority of patients (97%) reported at least one ad-
verse event during the treatment phase and, in gen-
eral, occurred at similar rates between the two groups
(Table 3). These adverse events were in most cases (85%)
considered by the investigator not related to study medica-
tion and the majority (91%) were rated mild-to-moderate
in intensity. A total of 39 adverse events (25 in the 200-
day group and 14 in the 100-day group) were considered
probably related to study medication, mainly hematologic,
including leukopenia.
The overall reported incidence of leukopenia (regardless
of whether it was thought to be related to study medica-
tion or not) was 38% in the 200-day group versus 26% in
the 100-day group (Table 3). However, the median labora-
tory WBC counts were similar between the two groups,
even when the 100-day patient group converted to placebo
for the later 100 days. Furthermore, the incidences of re-
ported neutropenia, febrile neutropenia, agranulocytosis,
anemia, thrombocytopenia and pancytopenia were compa-
rable between the two groups. The majority of leukopenia
cases resolved with or without treatment or study med-
ication adjustment. However, 4% of patients (7/156) in
the 200-day group had leukopenia that led to discontin-
uation of study medication compared with <1% of pa-
tients (1/164) in the 100-day group. Of the 113 reported
cases of leukopenia, 16 (14%) were classified as grade
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Figure 2: Kaplan–Meier plot of
time to cytomegalovirus dis-
ease up to month 12 posttrans-
plant.
3 or 4 according to their laboratory values. Overall, the
use of granulocyte-colony stimulating factor (G-CSF) was
similar between the two groups 14% (22/156) versus 13%
(22/164).
The incidence of neutropenia was comparable between
the groups overall and from study day 100 onward, when
patients in the day-100 group were taking placebo tablets
(15% in both groups overall [Table 3], and 5% (n = 8) in the
200-day group and 3% (n = 5) in the 100-day group after
study day 100).
The incidence of gastrointestinal disorders in the two
groups was 61% (95/156) and 52% (85/164), respectively,
with the majority being diarrhea (Table 3). Interestingly,
the incidence of gastrointestinal disorders was similar
from study day 100 onward, when patients in the 100-day
group were taking placebo tablets (21% (32/156) and 19%
(31/164) in the two groups, respectively). Table 4 summa-
rizes the common adverse events (occurring in ≥5% in
either group) experienced from study day 100 onward in
both groups.
Other outcomes
The proportion of patients in the ITT population with con-
firmed opportunistic infection (other than CMV disease)
up to 12 months posttransplant was significantly lower in
Table 2: Primary and selected secondary endpoints at 12 months (unless otherwise stated) after transplantation (intent-to-treat
population)
Valganciclovir 200 day Valganciclovir 100 day
Endpoint (n = 155) (n = 163) p-Value
Direct effects, n (%)
Cytomegalovirus (CMV) disease 25 (16.1%) 60 (36.8%) p < 0.0001
CMV disease at 9 months 22 (14.2%) 57 (35.0%) p < 0.0001
CMV disease at 6 months 11 (7.1%) 51 (31.3%) p < 0.0001
CMV disease (including assumed cases)1 36 (23.2%) 71 (43.6%) p < 0.0001
CMV viremia 58 (37.4%) 83 (50.9%) p = 0.015
CMV viremia at 9 months 55 (35.5%) 80 (49.1%) p = 0.013
CMV viremia at 6 months 29 18.7% 73 (44.8%) p < 0.0001
Indirect effects, (%)
Biopsy-proven acute rejection 17 (11.0%) 28 (17.2%) p = 0.114
Opportunistic infections 20 (12.9%) 44 (27.0%) p = 0.001
BK virus infection2 7 (4.5%) 5 (3.0%)
Oral candidiasis2 3 (1.9%) 8 (4.9%)
Human polyomavirus infection2 2 (1.3%) 5 (3.0%)
Oral herpes2 2 (1.3%) 5 (3.0%)
Candidiasis2 0 4 (2.4%)
Graft loss 3 (1.9%) 3 (1.8%) p = 0.934
Posttransplant diabetes mellitus3 15 (12.4%) 13 (10.6%) p = 0.815
1Patients without appropriate CMV disease status at the relevant time point and without a prior event were ‘assumed’ to have CMV
disease.
2Safety population.
315/121 and 13/123: Patients reporting diabetes mellitus at screening were excluded from the analysis of posttransplant diabetes mellitus.
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Figure 3: Kaplan–Meier plot of
time to cytomegalovirus viremia
up to month 12 posttransplant.
200-day group (p = 0.001; Table 2). This difference appears
mainly due to an imbalance in occurrence of opportunistic
infection during the first 50 days of therapy (0% [0/155]
vs. 31.8% [14/163] of the overall opportunistic infections
in the 200 days vs. 100 days groups, respectively). The pro-
portion of patients with confirmed posttransplantation dia-
betes mellitus was similar (p = 0.815) between the groups
up to month 12 (Table 2).
While the number of hospitalizations and the duration of
the hospitalization stay were comparable between the
groups (Table 5), the number of hospitalizations due to
CMV was lower in the 200-day group (10% vs. 21%).
All patients in the 200-day group survived to Month 12
posttransplant, but there were four deaths in the 100-day
group, which were considered to be unrelated to study
medication. Two patients died of septic shock on days 96
and 229 posttransplant, respectively, one patient died on
day 335 posttransplant due to hemorrhage, and one patient
died of sepsis on day 169 posttransplant.
Discussion
Late-onset CMV disease (occurring >3 months) is an in-
creasingly recognized problem following a standard 3-
month prophylaxis regimen. These data show a clear effi-
cacy benefit for the prevention of CMV disease by using a
200-day prophylaxis regimen compared with the standard
100 days’ prophylaxis in D+/R− kidney transplant recip-
ients. The relative and absolute risk reduction observed
with prolonged prophylaxis was 56% and 21%, respec-
tively. This corresponds to a number needed to treat of
approximately 5 in order to prevent each case of CMV dis-
ease up to 12 months posttransplant.
Figure 4: Peak cytomegalovirus
viral load up to month 12 post-
transplant (intent-to-treat popu-
lation).
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Figure 5: Median serum creati-
nine over time (lmol/L) (safety
population).
The extended duration of prophylaxis was associated with
a generally similar safety and tolerability profile compared
with the standard 100-day regimen. There were no new
safety concerns associated with the extension of valganci-
clovir CMV prophylaxis from 100 days to 200 days in kidney
transplant patients at high risk (D+/R-). However, there are
concerns that resistance may develop with prolonged ex-
posure to ganciclovir (18). Genotypic resistance testing is
currently being undertaken on all samples to evaluate the
incidence of resistance.
The CMV disease rates (36.8% for confirmed cases) seen
in this study at 12 months posttransplant for 100 days’ pro-
phylaxis are higher than those previously reported in the
pivotal PV16000 study (committee agreed: 17.2%) (19).
This difference may primarily relate to the definition of
CMV disease used on the two studies. This study used
a definition based on the AST recommendation for use
in clinical trials that more accurately reflects CMV disease
presentation in the modern era (i.e. many patients with viral
syndrome do not have fever) (17). The rate of investigator-
treated CMV disease in PV16000 was 30.5%, which is
more comparable to the rate observed in this study. Tis-
sue invasive disease was uncommon in this study with
only two cases (1.2%) occurring in the 100-day group,
but occurred in 9.2% of patients in the PV16000 study
(data not specified by type of organ transplant). This may
reflect current management strategies around CMV dis-
ease, which generally allow for rapid diagnosis through
blood tests rather than needing a biopsy sample.
An alternative approach to prophylaxis is a preemptive
strategy with regular laboratory monitoring and treatment
of asymptomatic CMV viremia. In a randomized study, both
preemptive and prophylactic (100 days) valganciclovir ther-
apy were shown to have similar effectiveness in the pre-
vention of symptomatic CMV disease after renal transplan-
tation (20). However, very few D+/R- patients were eval-
uated. Late-onset CMV disease appears to be less of a
problem with preemptive strategies, possibly because the
low-level viremia that occurs with preemptive therapy may
facilitate CMV-specific immune reconstitution and thus
mitigate the risk of late-onset CMV disease (21). However,
the possibility that preemptive strategies may be associ-
ated with poorer long-term graft survival compared with
prophylaxis is worrisome (22).
The possibility of merely pushing the disease onset pro-
gressively further out after transplantation, while not af-
fecting the actual incidence, is a significant concern with
extended duration of prophylaxis. However, this study
demonstrates a reduction in CMV disease incidence rather
than merely a delay in onset with the 200-day prophylac-
tic valganciclovir regimen. This finding is in line with data
from other studies that have suggested increasing the du-
ration of prophylaxis beyond the currently recommended
90–100-day window decreases the incidence of late-onset
CMV disease (12–14).
The study was not powered to detect differences in the
secondary endpoints of graft loss, BPAR or posttransplan-
tation diabetes mellitus. There were no significant differ-
ences between the groups in these endpoints. However,
there was a moderate trend toward less BPAR with 200
days of therapy versus 100 days of therapy (11% vs. 17%,
respectively, p = 0.114). This trend has been reported pre-
viously in other clinical trials, as was a study comparing
preemptive versus prophylaxis strategies in which the pro-
phylaxis was associated with improved kidney graft sur-
vival 4 years posttransplant (22,23). A difference in oppor-
tunistic infections (other than CMV) was observed, but this
should be interpreted with caution as the difference ap-
pears mainly due to an imbalance in occurrence during
the first 50 days of therapy (0% vs. 31.8% of the overall
1234 American Journal of Transplantation 2010; 10: 1228–1237
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Table 3: Overview of safety and common adverse events (inci-
dence ≥10% in either treatment group) (safety population)
Valganciclovir Valganciclovir
200 day 100 day
(n = 156) (n = 164)
Overview of safety
Patients with any adverse
event, n (%)





93 (60) 86 (52)
Patients with serious
adverse events, n (%)





13 (8) 13 (8)
Deaths during











Leukopenia 59 (38) 43 (26)
Diarrhea 49 (31) 43 (26)
Peripheral edema 30 (19) 35 (21)
Urinary tract infection 34 (22) 26 (16)
Anemia 24 (15) 30 (18)
Neutropenia 23 (15) 25 (15)
Tremor 26 (17) 19 (12)
Hypertension 19 (12) 21 (13)
Constipation 14 (9) 25 (15)
Hypophosphatemia 18 (12) 20 (12)
Increased blood creatinine 16 (10) 21 (13)
Hyperkalemia 15 (10) 20 (12)
Nausea 17 (11) 18 (11)
Pyrexia 14 (9) 20 (12)
Nasopharyngitis 12 (8) 17 (10)
Hypomagnesemia 10 (6) 17 (10)
Headache 9 (6) 16 (10)
Cough 7 (4) 17 (10)
1Events judged by the investigator to be remotely, possibly or
probably related to study treatment.
2Includes intercurrent illness.
3Occurring in ≥10% of patients between time of first drug intake
and 28 days after last drug intake. Multiple occurrences of same
adverse event in one patient counted only once.
opportunistic infections in the 200 days vs. 100 days
groups, respectively), when both groups of patients were
receiving the same prophylaxis regimen.
An important finding was that the number of hospitaliza-
tions for CMV disease was reduced by half, while hos-
pitalizations for other reasons (including adverse events)
were similar between the groups. In those who developed
Table 4: Common adverse events (incidence ≥5% in either treat-
ment group) occurring after Day 100 (safety population)
Valganciclovir Valganciclovir
200 day 100 day
Adverse events,1 n (%) (n = 156) (n = 164)
Leukopenia 30 (19) 7 (4)
Diarrhea 15 (10) 18 (11)
Urinary tract infection 11 (7) 11 (7)
Nasopharyngitis 10 (6) 7 (4)
Pyrexia 6 (4) 10 (6)
Upper respiratory tract infection 11 (7) 4 (2)
Cough 4 (3) 9 (5)
Neutropenia 8 (5) 5 (3)
1Occurring in ≥5% of patients between time of first drug intake
and 28 days after last drug intake. Multiple occurrences of same
adverse event in one patient counted only once.
detectable viremia, peak CMV viral loads were generally
lower in the 100-day group compared with the 200-day
group. In addition, the median length of hospital stay per
patient was reduced by around 1 day. These results sug-
gest that extending prophylaxis to 200 days may have fa-
vorable economic benefits. Indeed, 6 months’ prophylaxis
with valganciclovir combined with a one-time assessment
of viremia has been shown to be cost-effective from a
US societal perspective in reducing CMV infection and dis-
ease in D+/R− kidney transplant recipients (24). A formal
pharmacoeconomic analysis of the data from this study is
currently in progress.
There are some limitations to this study. First, immuno-
suppressive regimens were not controlled as part of the
trial and were at the discretion of the investigator. How-
ever, no investigational immunosuppression agents were
permitted and so the regimens used likely reflect current
Table 5: Summary of hospitalization data up to Month 12 (safety
population)
Valganciclovir Valganciclovir
200 day 100 day
(n = 156) (n = 164)
Hospitalizations per patient, n (%)
0 55 (35.3) 62 (37.8)
1 58 (37.2) 39 (23.8)
2 16 (10.3) 37 (22.6)
3 12 (7.7) 13 (7.9)
4 6 (3.8) 8 (4.9)
5 5 (3.2) 3 (1.8)





4.0 (0, 108) 5.0 (0, 93)
Principal reason for each hospitalization episode, n (%)
N 202 216
Cytomegalovirus 21 (10.4) 45 (20.8)
Adverse event 145 (71.8) 146 (67.6)
Other 36 (17.8) 25 (11.6)
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practice. It should be noted that no large multicenter ran-
domized trial of CMV prevention has ever mandated spe-
cific immunosuppression regimens. Second, HLA match-
ing was not analyzed in our study. Poor HLA-B and -DR
matching (i.e ≤2 matching) has been shown to significantly
reduce the incidence of CMV infection in SOT recipients
(16,25). Nonetheless, the randomization procedures under-
taken in our study would have minimized HLA-matching
bias between the two groups. Third, since this trial was
restricted to kidney transplant recipients, it is unknown if
these results can be extended to other transplant recipi-
ents or other risk categories such as D+/R+. In addition,
data on discontinuation of antimetabolite use for drug-
induced leukopenia or CMV viremia were not assessed
in our study. Although total G-CSF used was captured, a
detailed analysis of its use was not assessed. This informa-
tion may have helped better understand the clinical conse-
quences of drug-related adverse effects. Strengths of this
trial include the large sample size, the randomized double-
blinded design, and the use of more current definitions for
CMV disease.
In conclusion, this study demonstrated that extending val-
ganciclovir prophylaxis (900 mg once daily) to 200 days
in high-risk patients significantly reduces the incidence of
CMV disease and viremia up to 12 months compared with
100 days of prophylaxis. The extended duration of pro-
phylaxis had a generally similar tolerability and safety pro-
file. Based on these results, extending CMV prophylaxis
to approximately 6 months in high-risk kidney transplant
patients is a reasonable recommendation that appears to
provide a significant benefit.
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